Ludwig researchers present new findings at the 2017 ASCO Annual Meeting

Ludwig Cancer Research released today the full scope of Ludwig's participation at this year's American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6. Ludwig scientists will present findings on efforts to diagnose and treat a variety of cancers, including melanoma, glioblastoma, multiple myeloma and lymphoma.

"The ASCO Annual Meeting provides a unique opportunity for scientists from around the world to share information about new and innovative treatment strategies and identify new research opportunities," said Bob Strausberg, deputy scientific director, Ludwig Institute for Cancer Research. "Ludwig is pleased to present data on many advances in cancer immunotherapy in particular, a field that has long been a focus of Ludwig research."

Ludwig scientists will present data from several clinical trials of combination immunotherapies, which are jointly managed by Ludwig's Clinical Trials Management team and the Cancer Research Institute's Anna-Maria Kellen Clinical Accelerator. These include the use of anti-CTLA-4 and anti-PD-1 antibodies to treat patients with advanced solid tumors, and select relapsed cancers, and multiple myeloma patients receiving high dose chemotherapy. Further, they will provide an update of a Phase II study to evaluate the safety and efficacy of an anti-PD-L1 therapy in glioblastoma patients.

Ludwig researchers will also share findings on other topics, including the potential use of circulating tumor DNA in early diagnosis and treatment, immunotherapy to treat pediatric patients, how changes to DNA repair genes influence checkpoint blockade therapy, identifying biomarkers for melanoma treatment, and diagnostic criteria for a type of lymphoma.

Click here for a comprehensive list of Ludwig scientists' activities at the Meeting.

Provided by Ludwig Institute for Cancer Research